Inclisiran: the preclinical discovery and development of a novel therapy for the treatment of atherosclerosis

References

• World Health Organization [Internet]. Cardiovascular diseases (CVDs). [Updated 2021 Jun 11; cited 2021 Jun 11]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
   Google Scholar
• Cholesterol Treatment Trialists;Collaboration CTT), Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. doi: 10.1016/s0140-6736(10)61350-5
   PubMed Web of Science ®Google Scholar
• Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014;24(10):1057–1066. doi: 10.1016/j.numecd.2014.05.009
   PubMed Web of Science ®Google Scholar
• De Vera MA, Bhole V, Burns LC, et al. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014;78(4):684–698. doi: 10.1111/bcp.12339
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397. doi: 10.1056/nejmoa1410489
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER steering committee and investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. doi: 10.1056/NEJMoa1615664
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. ODYSSEY outcomes committees and investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107. doi: 10.1056/NEJMoa1801174
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(44):4255–4255. doi: 10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• Byrne AR, Rossello X, Coughlan JJ, et al. ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44(37):3720–3826. doi: 10.1093/eurheartj/ehad191
   PubMed Web of Science ®Google Scholar
• Banach M, Penson PE, Vrablik M, et al. Optimal use of lipid-lowering therapy after acute coronary syndromes: a position paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacol Res. 2021;166:105499. doi: 10.1016/j.phrs.2021.105499
   PubMed Web of Science ®Google Scholar
• Rallidis LS, Tsamoulis D, Leventis I, et al. Extremely high-risk patients with acute coronary syndrome: how “extreme” should lipid-lowering therapy be if the LDL-C target <40 mg/dl is considered? Kardiol Pol. 2023;8(10):1012–1014. doi: 10.33963/kp.a2023.0147
   Google Scholar
• U.S. Food and Drug Administration [Internet]. Center for Drug Evaluation and Research. FDA approves add-on therapy to lower cholesterol in certain people. [Updated 2021 Dec 22; cited 2021 Dec 22]. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-therapy-lower-cholesterol-among-certain-high-risk-adults
   Google Scholar
• Zamecnik PC, Stephenson ML. Inhibition of rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA. 1978;75(1):280–284. doi: 10.1073/pnas.75.1.280
   PubMed Web of Science ®Google Scholar
• Bennett CF, Baker BF, Pham N, et al. Pharmacology of antisense drugs. Annu Rev Pharmacol Toxicol. 2017;57(1):81–105. doi: 10.1146/annurev-pharmtox-010716-104846
   PubMedGoogle Scholar
• Banach M, Surma S, Toth PP, et al. Endorsed by the international lipid expert panel (ILEP). 2023: the year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024? Arch Med Sci. 2023;19(6):1602–1615. doi: 10.5114/aoms/174743
   PubMed Web of Science ®Google Scholar
• Assessing the Impact of Lipoprotein (a) Lowering with Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients with CVD (Lp(a)horizon). NCT Number; NCT04023552. [Updated 2023 Nov 14; cited 2023 Nov 14]; Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04023552
   Google Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–811. doi: 10.1038/35888
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase rig-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004;5(7):730–737. doi: 10.1038/ni1087
   PubMed Web of Science ®Google Scholar
• Neumeier J, Meister G. siRNA specificity: RNAi mechanisms and strategies to reduce off-target effects. Front Plant Sci. 2021;28(11):526455. doi: 10.3389/fpls.2020.526455
   Google Scholar
• Alshaer W, Zureigat H, Karaki AA, et al. siRNA: Mechanism of action, challenges, and therapeutic approaches. Eur J Pharmacol. 2021;905:174178. doi: 10.1016/j.ejphar.2021.174178
   PubMed Web of Science ®Google Scholar
• Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med. 2017;9(1):60. doi: 10.1186/s13073-017-0450-0
   PubMed Web of Science ®Google Scholar
• Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRnas and siRnas. Cell. 2009 20;136(4):642–655. doi: 10.1016/j.cell.2009.01.035
   PubMed Web of Science ®Google Scholar
• Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA. 2003;100(3):928–933. doi: 10.1073/pnas.0335507100
   PubMed Web of Science ®Google Scholar
• Abifadel M, Varret M, Jean-Pierre Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–156. doi: 10.1038/ng1161
   PubMed Web of Science ®Google Scholar
• Spolitu S, Dai W, Zadroga JA, et al. Proprotein convertase subtilisin/kexin type 9 and lipid metabolism. Curr Opin Lipidol. 2019;30(3):186–191. doi: 10.1097/mol.0000000000000601
   PubMed Web of Science ®Google Scholar
• Kent ST, Rosenson RS, Avery CL, et al. PCSK9 loss-of-function variants, low-density lipoprotein cholesterol, and risk of coronary heart disease and stroke: data from 9 studies of blacks and whites. Circ Cardiovasc Genet. 2017;10(4):e001632. doi: 10.1161/circgenetics.116.001632
   PubMedGoogle Scholar
• Xia X, Peng Gu H, Gu H-M, et al. Regulation of PCSK9 expression and function: mechanisms and therapeutic implications. Front Cardiovasc Med. 2021;8:764038. doi: 10.3389/fcvm.2021.764038
   PubMed Web of Science ®Google Scholar
• Guedeney P, Giustino G, Sorrentino S, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2022;43(7):17–25. doi: 10.1093/eurheartj/ehz430
   Web of Science ®Google Scholar
• A Study of MK-0616 (Oral PCSK9 Inhibitor) in adults with hypercholesterolemia (MK-0616-013) CORALreef Lipids. NCT number: NCT05952856. [Updated 2024 May 6; cited 2024 May 6]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05952856
   Google Scholar
• Kosmas CE, Estrella AM, Sourlas A, et al. Inclisiran in Dyslipidemia. Drugs Today (Barc). 2021;57(5):311–319. doi: 10.1358/dot.2021.57.5.3277083
   PubMed Web of Science ®Google Scholar
• Lee EG, Mazzola AM, Braun MC, et al. Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models. Circulation. 2023;147(3):242–253. doi: 10.1161/circulationaha.122.062132
   PubMed Web of Science ®Google Scholar
• Kosmas CE, DeJesus E, Morcelo R, et al. Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy. Drugs Context. 2017;6:212511. doi: 10.7573/dic.212511
   PubMedGoogle Scholar
• Kosmas CE, Muñoz Estrella A, Sourlas A, et al. Inclisiran: a new promising agent in the management of hypercholesterolemia. Diseases. 2018;6(3):63. doi: 10.3390/diseases6030063
   PubMedGoogle Scholar
• Merćep I, Friščić N, Strikić D, et al. Advantages and disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9—a narrative review. Cardiovasc Ther. 2022;10(2022):8129513. doi: 10.1155/2022/8129513
   Google Scholar
• Migliorati JM, Jin J, Zhong X, et al. siRNA drug leqvio (inclisiran) to lower cholesterol. Trends Pharmacol Sci. 2022;43(5):455–456. doi: 10.1016/j.tips.2022.02.003
   PubMed Web of Science ®Google Scholar
• Wright RS, Collins MG, Stoekenbroeket RM, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of Inclisiran: an analysis of the ORION-7 and ORION-1 studies. Mayo Clin Proc. 2020;95(1):77–89. doi: 10.1016/j.mayocp.2019.08.021
   PubMed Web of Science ®Google Scholar
• Kallend D, Stoekenbroek R, He Y, et al. Pharmacokinetics and pharmacodynamics of Inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. J Clin Lipidol. 2022;16(2):208–219. doi: 10.1016/j.jacl.2022.01.001
   PubMed Web of Science ®Google Scholar
• Frank-Kamenetsky M, Grefhorst A, Andersonet NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA. 2008;105(33):11915–11920. doi: 10.1073/pnas.0805434105
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41–51. doi: 10.1056/nejmoa1609243
   PubMed Web of Science ®Google Scholar
• Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430–1440. doi: 10.1056/nejmoa1615758
   PubMed Web of Science ®Google Scholar
• Leiter LA, Teoh H, Kallend D, et al. Inclisiran Lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial. Diabetes Care. 2019;42(1):173–176. doi: 10.2337/dc18-1491
   PubMed Web of Science ®Google Scholar
• Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 doses of Inclisiran on low-density lipoprotein cholesterol levels. JAMA Cardiol. 2019;4(11):1067–1075. doi: 10.1001/jamacardio.2019.3502
   PubMed Web of Science ®Google Scholar
• Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11(2):109–119. doi: 10.1016/s2213-8587(22)00353-9
   PubMed Web of Science ®Google Scholar
• Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–1519. doi: 10.1056/nejmoa1912387
   PubMed Web of Science ®Google Scholar
• Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520–1530. doi: 10.1056/nejmoa1913805
   PubMed Web of Science ®Google Scholar
• Hovingh GK, Lepor NE, Kallend D, et al. Inclisiran durably lowers low-density lipoprotein cholesterol and proprotein convertase subtilisin/kexin type 9 expression in homozygous familial hypercholesterolemia: the ORION-2 Pilot Study. Circulation. 2020;141(22):1829–1831. doi: 10.1161/circulationaha.119.044431
   PubMed Web of Science ®Google Scholar
• Raal F, Durst R, Bi R, et al. Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. Circulation. 2024;149(5):354–362. doi: 10.1161/circulationaha.122.063460
   PubMed Web of Science ®Google Scholar
• Trial to assess the effect of long term dosing of inclisiran in subjects with high CV risk and elevated LDL-C (ORION-8). NCT number: NCT03814187. [Updated 2024 Mar 6; cited 2024 Mar 6]. Available from: https://clinicaltrials.gov/study/NCT03814187
   Google Scholar
• Katsiki N, Vrablik M, Banach M, et al. Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a). Pharmaceuticals (Basel). 2023 12;16(4):577. doi: 10.3390/ph16040577
   PubMedGoogle Scholar
• A study of inclisiran to prevent cardiovascular events in high-risk primary prevention patients. NCT number: NCT05739383. [Updated 2024 Jan 29; cited 2024 Jan 29]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05739383
   Google Scholar
• A randomized trial assessing the effects of inclisiran on clinical outcomes among people with cardiovascular disease (ORION-4). NCT number: NCT03705234. [Updated 2023 Nov 2; cited 2023 Nov 2]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT03705234
   Google Scholar
• Study of inclisiran to prevent cardiovascular (CV) events in participants with established cardiovascular disease (VICTORION-2P). NCT number: NCT05030428. [Updated 2024 Mar 1; cited 2024 Mar 1]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05030428
   Google Scholar
• Padam P, Barton L, Wilson S, et al. Lipid lowering with Inclisiran: a real-world single-centre experience. Open Heart. 2022;9(2):002184. doi: 10.1136/openhrt-2022-002184
   PubMed Web of Science ®Google Scholar
• Mulder JWCM, Galema-Boers AMH, van Lennep JER, et al. First clinical experiences with inclisiran in a real-world setting. J Clin Lipidol. 2023;17(6):818–827. doi: 10.1016/j.jacl.2023.09.005
   PubMed Web of Science ®Google Scholar
• Kosmas CE, Estrella AM, Skavdis A, et al. Inclisiran for the treatment of cardiovascular disease: a short review on the emerging data and therapeutic potential. Ther Clin Risk Manag. 2020; 16:1031–1037. doi:10.2147/tcrm.s230592
   PubMed Web of Science ®Google Scholar
• Desai NR, Campbell C, Electricwala B, et al. Cost effectiveness of inclisiran in atherosclerotic cardiovascular patients with elevated low-density lipoprotein cholesterol despite statin use: a threshold analysis. Am J Cardiovasc Drugs. 2022;22(5):545–556. doi: 10.1007/s40256-022-00534-9
   PubMed Web of Science ®Google Scholar
• Galactionova K, Salari P, Mattliet R, et al. cost-effectiveness, burden of disease and budget impact of inclisiran: dynamic cohort modelling of a real-world population with cardiovascular disease. PharmacoEconomics. 2022;40(8):791–806. doi: 10.1007/s40273-022-01152-8
   PubMed Web of Science ®Google Scholar